{"pmid":32427774,"title":"Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases.","text":["Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases.","BACKGROUND: Coronavirus patients demonstrate varying degrees of respiratory insufficiency; many will progress to respiratory failure with a severe version of acute respiratory distress syndrome (ARDS) refractory to traditional supportive strategies. Providers must consider alternative therapies to deter or prevent the cascade of decompensation to fulminant respiratory failure. METHODS: This is a case-series of five COVID-19 positive patients who demonstrated severe hypoxemia, declining respiratory performance, and escalating oxygen requirements. Patients met the following criteria: COVID-19 positivity, worsening respiratory performance, severe hypoxemia (PaO2<80) despite traditional supportive measures, escalating supplemental oxygen requirements and D-dimer greater than 1.5mug/mL. All patients received protocol directed thrombolytic therapy with Tissue Plasminogen Activator (tPA). RESULTS: All five patients improved without deleterious effects of thrombolytic therapy. Patient one was on maximum ventilator support, paralytics, and prone positioning without improvement. During tPA administration his P/F ratio improved from 69 to 127. Ventilator support was weaned immediately on post-treatment day 1 and he was extubated on post treatment day 12. Our second through fifth patients were not intubated at time of initiation of tPA therapy. These patients each required significant oxygen supplementation trending toward intubation. After tPA therapy, all patients demonstrated a noticeable increase in PaO2 values overtime. Three of these patients avoided intubation due to COVID-19 associated respiratory failure. CONCLUSIONS: Administration of thrombolytics was followed by overall improvement in patients' oxygen requirements, and in three cases, prevented progression to mechanical ventilation, without deleterious effects. Clinical trials of thrombolytic therapy would further serve to underscore the efficacy and utility of this therapy. LEVEL OF EVIDENCE: Level V- Case series of therapeutic effect.","J Trauma Acute Care Surg","Benjamin Christie, D 3rd","Nemec, Hannah M","Scott, Anthony M","Buchanan, John T","Franklin, Christopher M","Ahmed, Aftab","Khan, Muhammad S","Callender, Charles W","James, Erskine A","Christie, Amy B","Ashley, Dennis W","32427774"],"abstract":["BACKGROUND: Coronavirus patients demonstrate varying degrees of respiratory insufficiency; many will progress to respiratory failure with a severe version of acute respiratory distress syndrome (ARDS) refractory to traditional supportive strategies. Providers must consider alternative therapies to deter or prevent the cascade of decompensation to fulminant respiratory failure. METHODS: This is a case-series of five COVID-19 positive patients who demonstrated severe hypoxemia, declining respiratory performance, and escalating oxygen requirements. Patients met the following criteria: COVID-19 positivity, worsening respiratory performance, severe hypoxemia (PaO2<80) despite traditional supportive measures, escalating supplemental oxygen requirements and D-dimer greater than 1.5mug/mL. All patients received protocol directed thrombolytic therapy with Tissue Plasminogen Activator (tPA). RESULTS: All five patients improved without deleterious effects of thrombolytic therapy. Patient one was on maximum ventilator support, paralytics, and prone positioning without improvement. During tPA administration his P/F ratio improved from 69 to 127. Ventilator support was weaned immediately on post-treatment day 1 and he was extubated on post treatment day 12. Our second through fifth patients were not intubated at time of initiation of tPA therapy. These patients each required significant oxygen supplementation trending toward intubation. After tPA therapy, all patients demonstrated a noticeable increase in PaO2 values overtime. Three of these patients avoided intubation due to COVID-19 associated respiratory failure. CONCLUSIONS: Administration of thrombolytics was followed by overall improvement in patients' oxygen requirements, and in three cases, prevented progression to mechanical ventilation, without deleterious effects. Clinical trials of thrombolytic therapy would further serve to underscore the efficacy and utility of this therapy. LEVEL OF EVIDENCE: Level V- Case series of therapeutic effect."],"journal":"J Trauma Acute Care Surg","authors":["Benjamin Christie, D 3rd","Nemec, Hannah M","Scott, Anthony M","Buchanan, John T","Franklin, Christopher M","Ahmed, Aftab","Khan, Muhammad S","Callender, Charles W","James, Erskine A","Christie, Amy B","Ashley, Dennis W"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32427774","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1097/TA.0000000000002787","topics":["Case Report"],"weight":1,"_version_":1667252837939150848,"score":9.490897,"similar":[{"pmid":32427773,"title":"Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA): A Case Series.","text":["Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA): A Case Series.","The COVID-19 pandemic has led to unprecedented stresses on modern medical systems, overwhelming the resource infrastructure in numerous countries while presenting a unique series of pathophysiologic clinical findings. Thrombotic coagulopathy is common in critically ill patients suffering from COVID-19, with associated high rates of respiratory failure requiring prolonged periods of mechanical ventilation. Here we report a case series of five patients suffering from profound, medically refractory COVID-19 associated respiratory failure who were treated with fibrinolytic therapy using tissue plasminogen activator (tPA, Alteplase). All five patients appeared to have an improved respiratory status following tPA administration: one patient had an initial marked improvement that partially regressed after several hours, one patient had transient improvements that were not sustained, and three patients had sustained clinical improvements following tPA administration.","J Trauma Acute Care Surg","Barrett, Christopher D","Oren-Grinberg, Achikem","Chao, Edward","Moraco, Andrew H","Martin, Matthew J","Reddy, Srinivas H","Ilg, Annette M","Jhunjhunwala, Rashi","Uribe, Marco","Moore, Hunter B","Moore, Ernest E","Baedorf-Kassis, Elias N","Krajewski, Megan L","Talmor, Daniel S","Shaefi, Shahzad","Yaffe, Michael B","32427773"],"abstract":["The COVID-19 pandemic has led to unprecedented stresses on modern medical systems, overwhelming the resource infrastructure in numerous countries while presenting a unique series of pathophysiologic clinical findings. Thrombotic coagulopathy is common in critically ill patients suffering from COVID-19, with associated high rates of respiratory failure requiring prolonged periods of mechanical ventilation. Here we report a case series of five patients suffering from profound, medically refractory COVID-19 associated respiratory failure who were treated with fibrinolytic therapy using tissue plasminogen activator (tPA, Alteplase). All five patients appeared to have an improved respiratory status following tPA administration: one patient had an initial marked improvement that partially regressed after several hours, one patient had transient improvements that were not sustained, and three patients had sustained clinical improvements following tPA administration."],"journal":"J Trauma Acute Care Surg","authors":["Barrett, Christopher D","Oren-Grinberg, Achikem","Chao, Edward","Moraco, Andrew H","Martin, Matthew J","Reddy, Srinivas H","Ilg, Annette M","Jhunjhunwala, Rashi","Uribe, Marco","Moore, Hunter B","Moore, Ernest E","Baedorf-Kassis, Elias N","Krajewski, Megan L","Talmor, Daniel S","Shaefi, Shahzad","Yaffe, Michael B"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32427773","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1097/TA.0000000000002786","topics":["Case Report"],"weight":1,"_version_":1667252837920276480,"score":320.0617},{"pmid":32312290,"pmcid":"PMC7169373","title":"Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis.","text":["Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis.","BACKGROUND: COVID-19 threatens to quickly overwhelm our existing critical care infrastructure in the USA. Systemic tissue plasminogen activator (tPA) has been previously demonstrated to improve PaO2/FiO2 (mmHg) when given to critically ill patients with acute respiratory distress syndrome (ARDS). It is unclear to what extent tPA may impact population-based survival during the current US COVID-19 pandemic. METHODS: A decision analytic Markov state transition model was created to simulate the life critically ill COVID-19 patients as they transitioned to either recovery or death. Two patient groups were simulated (50,000 patients in each group); (1) Patients received tPA immediately upon diagnosis of ARDS and (2) patients received standard therapy for ARDS. Base case critically ill COVID-19 patients were defined as having a refractory PaO2/FiO2 of < 60 mmHg (salvage use criteria). Transition from severe to moderate to mild ARDS, recovery, and death were estimated. Markov model parameters were extracted from existing ARDS/COVID-19 literature. RESULTS: The use of tPA was associated with reduced mortality (47.6% [tTPA] vs. 71.0% [no tPA]) for base case patients. When extrapolated to the projected COVID-19 eligible for salvage use tPA in the USA, peak mortality (deaths/100,000 patients) was reduced for both optimal social distancing (70.5 [tPA] vs. 75.0 [no tPA]) and no social distancing (158.7 [tPA] vs. 168.8 [no tPA]) scenarios. CONCLUSIONS: Salvage use of tPA may improve recovery of ARDS patients, thereby reducing COVID-19-related mortality and ensuring sufficient resources to manage this pandemic.","World J Emerg Surg","Choudhury, Rashikh","Barrett, Christopher D","Moore, Hunter B","Moore, Ernest E","McIntyre, Robert C","Moore, Peter K","Talmor, Daniel S","Nydam, Trevor L","Yaffe, Michael B","32312290"],"abstract":["BACKGROUND: COVID-19 threatens to quickly overwhelm our existing critical care infrastructure in the USA. Systemic tissue plasminogen activator (tPA) has been previously demonstrated to improve PaO2/FiO2 (mmHg) when given to critically ill patients with acute respiratory distress syndrome (ARDS). It is unclear to what extent tPA may impact population-based survival during the current US COVID-19 pandemic. METHODS: A decision analytic Markov state transition model was created to simulate the life critically ill COVID-19 patients as they transitioned to either recovery or death. Two patient groups were simulated (50,000 patients in each group); (1) Patients received tPA immediately upon diagnosis of ARDS and (2) patients received standard therapy for ARDS. Base case critically ill COVID-19 patients were defined as having a refractory PaO2/FiO2 of < 60 mmHg (salvage use criteria). Transition from severe to moderate to mild ARDS, recovery, and death were estimated. Markov model parameters were extracted from existing ARDS/COVID-19 literature. RESULTS: The use of tPA was associated with reduced mortality (47.6% [tTPA] vs. 71.0% [no tPA]) for base case patients. When extrapolated to the projected COVID-19 eligible for salvage use tPA in the USA, peak mortality (deaths/100,000 patients) was reduced for both optimal social distancing (70.5 [tPA] vs. 75.0 [no tPA]) and no social distancing (158.7 [tPA] vs. 168.8 [no tPA]) scenarios. CONCLUSIONS: Salvage use of tPA may improve recovery of ARDS patients, thereby reducing COVID-19-related mortality and ensuring sufficient resources to manage this pandemic."],"journal":"World J Emerg Surg","authors":["Choudhury, Rashikh","Barrett, Christopher D","Moore, Hunter B","Moore, Ernest E","McIntyre, Robert C","Moore, Peter K","Talmor, Daniel S","Nydam, Trevor L","Yaffe, Michael B"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32312290","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1186/s13017-020-00305-4","keywords":["acute respiratory distress syndrome (ards)","covid-19","fibrinolysis","markov","pulmonary failure","tissue plasminogen activator (tpa)"],"locations":["USA","US","USA","USA"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Treatment"],"weight":1,"_version_":1666138493567369216,"score":277.464},{"pmid":32329246,"title":"Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.","text":["Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.","The global pandemic of coronavirus disease 2019 (COVID-19) is associated with the development of acute respiratory distress syndrome (ARDS), which requires ventilation in critically ill patients. The pathophysiology of ARDS results from acute inflammation within the alveolar space and prevention of normal gas exchange. The increase in proinflammatory cytokines within the lung leads to recruitment of leukocytes, further propagating the local inflammatory response. A consistent finding in ARDS is the deposition of fibrin in the air spaces and lung parenchyma. COVID-19 patients show elevated D-Dimers and fibrinogen. Fibrin deposits are found in the lungs of patients due to the dysregulation of the coagulation and fibrinolytic systems. Tissue factor (TF) is exposed on damaged alveolar endothelial cells and on the surface of leukocytes promoting fibrin deposition, while significantly elevated levels of plasminogen activator inhibitor 1 (PAI-1) from lung epithelium and endothelial cells create a hypofibrinolytic state. Prophylaxis treatment of COVID-19 patients with low molecular weight heparin (LMWH) is important to limit coagulopathy. However, to degrade pre-existing fibrin in the lung it is essential to promote local fibrinolysis. In this review, we discuss the repurposing of fibrinolytic drugs, namely tissue-type plasminogen activator (tPA), to treat COVID-19 associated ARDS. tPA is an approved intravenous thrombolytic treatment, and the nebulizer form has been shown to be effective in plastic bronchitis and is currently in Phase II clinical trial. Nebulizer plasminogen activators may provide a targeted approach in COVID-19 patients to degrade fibrin and improving oxygenation in critically ill patients.","J Thromb Haemost","Whyte, Claire S","Morrow, Gael B","Mitchell, Joanne L","Chowdary, Pratima","Mutch, Nicola J","32329246"],"abstract":["The global pandemic of coronavirus disease 2019 (COVID-19) is associated with the development of acute respiratory distress syndrome (ARDS), which requires ventilation in critically ill patients. The pathophysiology of ARDS results from acute inflammation within the alveolar space and prevention of normal gas exchange. The increase in proinflammatory cytokines within the lung leads to recruitment of leukocytes, further propagating the local inflammatory response. A consistent finding in ARDS is the deposition of fibrin in the air spaces and lung parenchyma. COVID-19 patients show elevated D-Dimers and fibrinogen. Fibrin deposits are found in the lungs of patients due to the dysregulation of the coagulation and fibrinolytic systems. Tissue factor (TF) is exposed on damaged alveolar endothelial cells and on the surface of leukocytes promoting fibrin deposition, while significantly elevated levels of plasminogen activator inhibitor 1 (PAI-1) from lung epithelium and endothelial cells create a hypofibrinolytic state. Prophylaxis treatment of COVID-19 patients with low molecular weight heparin (LMWH) is important to limit coagulopathy. However, to degrade pre-existing fibrin in the lung it is essential to promote local fibrinolysis. In this review, we discuss the repurposing of fibrinolytic drugs, namely tissue-type plasminogen activator (tPA), to treat COVID-19 associated ARDS. tPA is an approved intravenous thrombolytic treatment, and the nebulizer form has been shown to be effective in plastic bronchitis and is currently in Phase II clinical trial. Nebulizer plasminogen activators may provide a targeted approach in COVID-19 patients to degrade fibrin and improving oxygenation in critically ill patients."],"journal":"J Thromb Haemost","authors":["Whyte, Claire S","Morrow, Gael B","Mitchell, Joanne L","Chowdary, Pratima","Mutch, Nicola J"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329246","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/jth.14872","keywords":["fibrin","fibrinolysis","plasminogen activator inhibitor 1","respiratory distress syndrome (adult)","sars virus","tissue plasminogen activator"],"locations":["ARDS","nebulizer","Nebulizer"],"e_drugs":["Heparin, Low-Molecular-Weight"],"topics":["Treatment"],"weight":1,"_version_":1666138494690394113,"score":259.5513},{"pmid":32320506,"title":"Early Self-Proning in Awake, Non-intubated Patients in the Emergency Department: A Single ED's Experience during the COVID-19 Pandemic.","text":["Early Self-Proning in Awake, Non-intubated Patients in the Emergency Department: A Single ED's Experience during the COVID-19 Pandemic.","OBJECTIVE: Prolonged and unaddressed hypoxia can lead to poor patient outcomes. Proning has become a standard treatment in the management of patients with ARDS who have difficulty achieving adequate oxygen saturation. The purpose of this study was to describe the use of early proning of awake, non-intubated patients in the emergency department (ED) during the COVID-19 pandemic. METHODS: This pilot study was carried out in a single urban ED in New York City. We included patients suspected of having COVID19 with hypoxia on arrival. A standard pulse oximeter was used to measure SpO2. SpO2 measurements were recorded at triage and after five minutes of proning. Supplemental oxygenation methods included non-rebreather mask (NRB) and nasal cannula. We also characterized post-proning failure rates of intubation within the first 24 hours of arrival to the ED. RESULTS: Fifty patients were included. Overall, the median SpO2 at triage was 80% (IQR 69 to 85). After application of supplemental oxygen was given to patients on room air it was 84% (IQR 75 to 90). After 5 minutes of proning was added SpO2 improved to 94% (IQR 90 to 95). Comparison of the pre- to post-median by the Wilcoxon Rank-sum test yielded P=0.001. Thirteen patients (24%) failed to improve or maintain their oxygen saturations and required endotracheal intubation within 24 hours of arrival to the ED. CONCLUSION: Awake early self-proning in the emergency department demonstrated improved oxygen saturation in our COVID-19positive patients. Further studies are needed to support causality and determine the effect of proning on disease severity and mortality.","Acad Emerg Med","Caputo, Nicholas D","Strayer, Reuben J","Levitan, Richard","32320506"],"abstract":["OBJECTIVE: Prolonged and unaddressed hypoxia can lead to poor patient outcomes. Proning has become a standard treatment in the management of patients with ARDS who have difficulty achieving adequate oxygen saturation. The purpose of this study was to describe the use of early proning of awake, non-intubated patients in the emergency department (ED) during the COVID-19 pandemic. METHODS: This pilot study was carried out in a single urban ED in New York City. We included patients suspected of having COVID19 with hypoxia on arrival. A standard pulse oximeter was used to measure SpO2. SpO2 measurements were recorded at triage and after five minutes of proning. Supplemental oxygenation methods included non-rebreather mask (NRB) and nasal cannula. We also characterized post-proning failure rates of intubation within the first 24 hours of arrival to the ED. RESULTS: Fifty patients were included. Overall, the median SpO2 at triage was 80% (IQR 69 to 85). After application of supplemental oxygen was given to patients on room air it was 84% (IQR 75 to 90). After 5 minutes of proning was added SpO2 improved to 94% (IQR 90 to 95). Comparison of the pre- to post-median by the Wilcoxon Rank-sum test yielded P=0.001. Thirteen patients (24%) failed to improve or maintain their oxygen saturations and required endotracheal intubation within 24 hours of arrival to the ED. CONCLUSION: Awake early self-proning in the emergency department demonstrated improved oxygen saturation in our COVID-19positive patients. Further studies are needed to support causality and determine the effect of proning on disease severity and mortality."],"journal":"Acad Emerg Med","authors":["Caputo, Nicholas D","Strayer, Reuben J","Levitan, Richard"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320506","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/acem.13994","locations":["New York","Awake"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Treatment"],"weight":1,"_version_":1666138493757161472,"score":205.75458},{"pmid":32275753,"pmcid":"PMC7184376","title":"Plasminogen improves lung lesions and hypoxemia in patients with COVID-19.","text":["Plasminogen improves lung lesions and hypoxemia in patients with COVID-19.","BACKGROUND: Lungs from patients with coronavirus disease 2019 (COVID-19) have shown typical signs of acute respiratory distress syndrome (ARDS), formation of hyaline membrane mainly composed of fibrin, and 'ground-glass' opacity. Previously, we showed plasminogen itself is a key regulator in fibrin degradation, wound healing and infection. AIM: We aimed to investigate whether plasminogen can improve lung lesions and hypoxemia of COVID-19. DESIGN: Thirteen clinically moderate, severe or critical COVID-19 patients were treated with atomization inhalation of freeze-dried plasminogen. METHODS: Levels of their lung lesions, oxygen saturation and heart rates were compared before and after treatment by CT scanning images and patient monitor. RESULTS: After plasminogen inhalation, conditions of lung lesions in 5 clinically moderate patients have quickly improved, shown as the decreased range and density of 'ground glass' opacity. Improvements of oxygen saturation were observed in 6 clinically severe patients. In the 2 patients with critical conditions, the oxygen levels have significantly increased from 79-82% to 91% just about 1 hour after the first inhalation. In 8 of 13 patients the heart rates had slowed down. For the 5 clinically moderate patients, the difference is even statistically significant. Furthermore, a general relief of chest tightness was observed. CONCLUSION: Whereas it is reported that plasminogen is dramatically increased in adults with ARDS, this study suggests that additional plasminogen may be effective and efficient in treating lung lesions and hypoxemia during COVID-19 infections. Although further studies are needed, this study highlights a possible hope of efficiently combating this rapid epidemic emergency.","QJM","Wu, Yuanyuan","Wang, Ting","Guo, Chunying","Zhang, Dongmei","Ge, Xiaojing","Huang, Zhaoxing","Zhou, Xianshan","Li, Yinping","Peng, Qingzhen","Li, Jinan","32275753"],"abstract":["BACKGROUND: Lungs from patients with coronavirus disease 2019 (COVID-19) have shown typical signs of acute respiratory distress syndrome (ARDS), formation of hyaline membrane mainly composed of fibrin, and 'ground-glass' opacity. Previously, we showed plasminogen itself is a key regulator in fibrin degradation, wound healing and infection. AIM: We aimed to investigate whether plasminogen can improve lung lesions and hypoxemia of COVID-19. DESIGN: Thirteen clinically moderate, severe or critical COVID-19 patients were treated with atomization inhalation of freeze-dried plasminogen. METHODS: Levels of their lung lesions, oxygen saturation and heart rates were compared before and after treatment by CT scanning images and patient monitor. RESULTS: After plasminogen inhalation, conditions of lung lesions in 5 clinically moderate patients have quickly improved, shown as the decreased range and density of 'ground glass' opacity. Improvements of oxygen saturation were observed in 6 clinically severe patients. In the 2 patients with critical conditions, the oxygen levels have significantly increased from 79-82% to 91% just about 1 hour after the first inhalation. In 8 of 13 patients the heart rates had slowed down. For the 5 clinically moderate patients, the difference is even statistically significant. Furthermore, a general relief of chest tightness was observed. CONCLUSION: Whereas it is reported that plasminogen is dramatically increased in adults with ARDS, this study suggests that additional plasminogen may be effective and efficient in treating lung lesions and hypoxemia during COVID-19 infections. Although further studies are needed, this study highlights a possible hope of efficiently combating this rapid epidemic emergency."],"journal":"QJM","authors":["Wu, Yuanyuan","Wang, Ting","Guo, Chunying","Zhang, Dongmei","Ge, Xiaojing","Huang, Zhaoxing","Zhou, Xianshan","Li, Yinping","Peng, Qingzhen","Li, Jinan"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275753","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1093/qjmed/hcaa121","keywords":["covid-19","sars-cov-2","ground-glass opacity","oxygen saturation","plasminogen"],"topics":["Treatment"],"weight":1,"_version_":1666138491710341120,"score":200.94603}]}